Maker of $1,000 hepatitis C pill put profit before patients: U.S. Senate

WASHINGTON -- The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, Senate investigators said Tuesday.A bipartisan report from the Senate Finance Committee concluded that California-based Gilead Sciences was focused on maximizing revenue even as the company's own analysis showed a lower price would allow more patients to be treated.Although the report focused on just o